MTND3P17

Across TCGA pan-cancer cohorts, MTND3P17 RNA differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of MTND3P17’s most consistent transcriptional readouts.

The strongest signal is observed in breast invasive carcinoma (BRCA), where MTND3P17 RNA is repressed in tumor relative to normal tissue. In most cancer types MTND3P17 is over-expressed in tumor, although a few such as BRCA show the opposite, repressed pattern.

BRCA and LUSC are the cancer types where MTND3P17 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MTND3P17 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BRCA	All	III,IV	−0.042	.045	4	view →
LUSC	All	All	+0.039	.031	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 2 strongest of 2 lineages.

MTND3P17–BRCA

Open the BRCA breakdown →